Abstract-Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. We, therefore, engineered a novel, designer peptide, which simultaneously targets the pGC-A (particulate guanylyl cyclase A) receptor and the MasR (Mas receptor), potentially representing an attractive cardiorenoprotective therapeutic for cardiovascular disease. We engineered a novel, bispecific receptor activator, NPA7, that represents the fusion of a 22-amino acid sequence of BNP (B-type natriuretic peptide; an endogenous ligand of pGC-A) with Ang 1-7 (angiotensin 1-7)-the 7-amino acid endogenous activator of MasR. We assessed NPA7's dual receptor activating actions in vitro (second messenger production and receptor interaction). Further, we performed an intravenous peptide infusion comparison study in normal canines to study its biological actions in vivo, including in the presence of an MasR antagonist. Our in vivo and in vitro studies demonstrate the successful synthesis of NPA7 as a bispecific receptor activator targeting pGC-A and MasR. In normal canines, NPA7 possesses enhanced natriuretic, diuretic, systemic, and renal vasorelaxing and cardiac unloading properties. Importantly, NPA7's actions are superior to that of the individual native pGC-A or MasR ligands. These studies advance NPA7 as a novel, bispecific designer peptide with potential cardiorenal therapeutic benefit for the treatment of cardiovascular disease, such as hypertension and heart failure. (Hypertension. 2019;73:900-909.
W
ith an estimated cost of $207 billion each year, cardiovascular disease (CVD), such as hypertension and heart failure (HF), is regarded as a major health burden worldwide. In the United States alone, CVD is the leading cause of mortality in men and women from different ethnic backgrounds, accounting for 1 in every 4 deaths, despite current optimal therapies and prevention strategies. 1, 2 Moreover, current drug therapies, such as ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers, have been shown to have relative efficacy in preventing the occurrence of cardiovascular events. 3 Thus, the development of innovative new drugs with novel modes of action is, therefore, a priority of great importance. 4 An emerging strategy in drug discovery has been the design and development of bispecific therapeutics. Bispecific drugs target 2 independent signaling pathways and aim to achieve therapeutic synergy that transcends the effects of single-pathway activation. As an example, this concept has been supported by the approval of the small molecule sacubitril/ valsartan for chronic and acute HF, which has also demonstrated efficacy in hypertension. [5] [6] [7] An increasingly recognized molecular target in cardiorenal therapeutics is the MasR (Mas receptor). Studies have established that the MasR possesses antiapoptotic, anti-inflammatory, vasodilatory, antithrombotic, and AT1R antagonizing actions by activation via its ligand Ang 1-7 (angiotensin 1-7) and its second messenger cAMP. [8] [9] [10] [11] This Ang 1-7/MasR axis has also been reported to be cardiorenal protective in models of hypertension, HF, diabetic nephropathy, and obesity. [12] [13] [14] [15] The therapeutic development of MasR has been limited, however, by the rapid in vivo degradation of Ang 1-7 16 .
A second molecular target that is well recognized to mediate cardiorenal protection in CVD is the pGC-A (particulate guanylyl cyclase A) receptor and its second messenger cyclic GMP (cGMP), for which the cardiac hormones ANP (atrial natriuretic peptide) and BNP (B-type natriuretic peptide) are its endogenous ligands. 17, 18 Indeed, activation of pGC-A/cGMP pathway mediates a number of key biological properties and includes natriuresis, diuresis, blood pressure (BP) lowering, inhibition of cardiomyocyte hypertrophy and fibroblast proliferation, browning of white adipocytes with enhanced energy utilization, suppression of inflammatory cytokines and T cells, and inhibition of aldosterone. [19] [20] [21] [22] [23] [24] Furthermore, chronic activation of pGC-A by adenoviral BNP gene delivery in spontaneously hypertensive rats reduced BP and protected against cardiac hypertrophy and diastolic dysfunction, whereas BNP knockout rats are characterized by hypertension and end-organ damage. 25, 26 Moreover, in humans with stable HF, chronic pGC-A augmentation with twice-daily subcutaneously BNP injections improved cardiorenal function and clinical symptoms. 27 Together, these experimental and human studies continue to support the therapeutic benefit of long-term pGC-A enhancement for cardiorenal protection.
Based on exploratory studies, we hypothesized that replacing the 9-amino acid (AA) N terminus of BNP1-32 with the MasR agonist Ang 1-7 would result in a novel peptide, we call NPA7, that successfully coactives both pGC-A and MasR. We also hypothesized that NPA7 would possess enhanced systemic and renal vasodilating, natriuretic, diuretic, and cardiac unloading properties that go beyond that mediated by either Ang 1-7 or BNP alone. Thus, we report the design, synthesis, in vitro validation of NPA7, and in vivo biological actions of a first-inclass, bispecific designer peptide with potentially beneficial efficacy for the treatment of CVD, such as hypertension and HF.
Methods
The authors declare that all supporting data are available within the article and its online-only Data Supplement.
Design and Synthesis of NPA7: First-in-Class
Bispecific pGC-A Receptor/MasR Peptide NPA7 was designed as a first-in-class bispecific peptide that fuses a 22-AA residue cassette of the human pGC-A receptor activator BNP with the 7-AA cassette sequence of the MasR agonist Ang 1-7 ( Figure  S1 in the online-only Data Supplement). NPA7 was synthesized by Fmoc solid phase methods on preloaded Nα-Fmoc-Nim-trityl-LHistidine Wang resin (Anaspec, Inc). The peptide chain was assembled from Nα-Fmoc protected AA on a Liberty Blue Microwave-Assisted Peptide Synthesizer (CEM Corp) according to the manufacturer's synthesis protocols. The peptide and its side-chain protecting groups were removed from the resin support by acid cleavage with a solution of 90% aqueous trifluoroacetic acid containing 2.5% triisopropylsilane (v/v) for 2 hours at room temperature. The crude linear NPA7 peptide was purified by preparative reversed-phase-high-performance liquid chromatography using an aqueous/acetonitrile gradient containing 0.1 % trifluoroacetic acid (v/v) on a reverse-phase C18 column (Phenomenex Jupiter 15 µ; 250×21.2 mm). The average mass of the purified linear NPA7 peptide was verified by electrospray ionization-time-of-flight mass spectrometry analysis on an Agilent 6224 time-of-flight liquid chromatography-mass spectometry instrument ( Figure S2A and S2B).
After synthesis of NPA7, the high-performance liquid chromatography purified linear NPA7 was oxidized with clear-ox resin (Peptides International) to form the cyclized ring between cysteine residues 8 and 24. Briefly, the peptide was mixed with the clear-ox resin at room temperature according to the manufacturer's protocol for 12 hours or until the resin developed a dark orange color indicating complete oxidation. The cyclized peptide was then repurified by reversed-phasehigh-performance liquid chromatography as described above. The average mass of the cyclized NPA7 peptide (observed, 3472.8 Da; calculated, 3473.1 Da) was verified by electrospray ionization-timeof-flight mass spectrometry ( Figure S2 ). Analytical reversed-phasehigh-performance liquid chromatography indicated that the purified cyclized peptide was >96% in homogeneity.
In Vitro Experiments
To assess activation of MasR and pGC-A, we utilized human embryonic kidney (HEK) 293 cells that stably overexpressed either the human pGC-A or human MasR.
pGC-A and MasR Interaction With NPA7 by AlphaScreen Luminescence Receptor Assay
NPA7 interaction with pGC-A and MasR was determined by the AlphaScreen luminescence proximity receptor assay as previously described with modifications. [28] [29] [30] The membrane protein fractions of transfected HEK cells and parental (nontransfected) cells were isolated by ProteoExtract Native Membrane Protein Extraction Kit (Calbiochem, San Diego, CA). Interaction of NPA7 with pGC-A was determined using reaction mixtures consisting of biotinylated NPA7 peptides (10 −6 M), 1.25 ug membrane protein fraction, 20 ug/mL anti-GFP (anti-green fluorescent protein) antibody-coated acceptor beads (PerkinElmer Life Sciences, Waltham, MA), and 20 ug/mL streptavidin-coated donor beads (PerkinElmer Life Sciences) in a 0.1% BSA, 0.1% Tween-20 PBS buffer. Interaction of NPA7 to MasR was determined using reaction mixtures that consisted of NPA7 peptides (10 , and 10 −5 M) were treated for 10 minutes to determine cAMP production (MasR second messenger). Note concentrations of peptides used in the MasR overexpressing cells were higher than concentrations used in pGC-A cells because cAMP levels are lower intracellularly and higher concentrations of MasR activators are required for cAMP generation. Seventy percent to 80% confluent cells at passages 2 through 6 were used for experiments. Briefly, cells were lysed and sonicated for 10 minutes after incubation with ligands. Cell lysates were centrifuged and supernatants were extracted, dried and reconstituted in 300 µL cGMP or cAMP and were assayed using a radioimmunoassay cGMP or radioimmunoassay cAMP kit, as described previously.
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In Vivo Experiments
Cardiorenal Actions of NPA7 in Normal Canines
Male mongrel canine studies were performed in accordance with the Animal Welfare Act and with approval of the Mayo Clinic Institutional Animal Care and Use Committee. Sixteen male mongrel dogs (weight, 22.0-30.0 kg) were assigned to infusion with one of the following: the MasR ligand Ang 1-7 (n=5), the pGC-A ligand BNP (n=5), or NPA7 (n=6). Study drugs in each group were infused in equimolar doses, 8.66 pmol×kg −1 ×min −1 (based on previous studies from our laboratory infusing BNP in healthy canines 32 ). Investigators were not blinded to treatments, but biochemical analysis was performed by technicians who were blinded to treatment. Groups were not randomized but performed in serial fashion. Normal mongrel dogs were included if deemed healthy by the Institutional Veterinarian Department.
On the evening before the acute study, canines were fasted with ad libitum access to water. On the day of the experiment, canines were anesthetized with intravenous pentobarbital (15-30 mg×kg , 12 cycles×min −1 (Harvard Apparatus, Millis, MA). The right femoral artery was cannulated for measurement of mean arterial pressure (MAP) and for blood sampling. The right femoral vein was cannulated for intravenous infusion of inulin and normal saline or peptide. The left kidney was exposed through a left flank incision. The left ureter was cannulated for continuous urine collection. An electromagnet flow probe (Carolina Medical Electronics, Inc, East Bend, NC) was placed on the left renal artery for measurement of renal blood flow. The right jugular vein was cannulated, and a Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA) was introduced for measurement of intracardiac pressures. Normal saline was infused at 1 mL×min −1 (infusion was temporarily discontinued during peptide infusion). After instrumentation, a 60-minute equilibrium period followed, and a 30-minute preinfusion (baseline) period was performed. baseline was followed by a 45-minute continuous infusion of Ang 1-7, BNP, or NPA7 (15 minutes lead-in drug infusion, 30 minutes clearance during drug infusion). Directly after discontinuation of peptide infusion, a 30-minute washout clearance was started, followed by two 30-minute recovery clearances (recovery 1 and recovery 2, respectively). During all clearances, hemodynamic parameters (IX/408 Data Acquisition System Hardware; iWorks System, Inc, Dover, NH) and intracardiac pressures were measured, and urine was collected. Blood was drawn halfway through each clearance and replaced with equal volume of normal saline.
Cardiorenal Actions of NPA7 in Normal Canines With MasR Blockade
To better understand the biological effects of NPA7's dual receptor activating properties with a special focus on MasR, we performed an intravenous coinfusion study of NPA7 with the MasR antagonist (MasR-i) A779 (Sigma-Aldrich, St. Louis, MO). Six male mongrel canines (weight, 22.5-30 kg) received coinfusion of 8.66 pmol×kg −1 ×min −1 NPA7 and 5.83 μg×kg −1 ×h −1 A779 with comparison with the NPA7-alone infusion canines as described above. Fasting of dogs, experimental setup of acute study, and data collection was done according to the abovementioned protocol. MasR-i was infused using a saphenous vein (0.2 mL/min).
Analyses of Neurohumoral and Renal Function
All urine and blood samples were stored immediately on ice after collection. After centrifugation (2500 rpm, at 4°C for 10 minutes), plasma and serum were aliquoted and stored at −80°C until analysis. Plasma and urine cGMP were determined by radioimmunoassay as described previously. 31, 32 Plasma and urine electrolytes were analyzed on a flame photometer (model 1L943; Instrumentation Laboratory, Lexington, MA). 31 Renal generation of cGMP was calculated as urine excretion of cGMP−(plasma cGMP×glomerular filtration rate).
Statistical Analyses
Data from in vitro experiments are presented as mean±SEM. For in vitro studies, treatment-induced differences were analyzed using Student t test. For in vivo studies, differences between groups were analyzed using 2-way repeated-measures ANOVA with Bonferroni test for multiple comparisons, and each group (Ang 1-7, BNP, and NPA7) was compared with the other 2 groups. Statistical comparison between NPA7 and NPA7+ MasR-i groups was also analyzed using 2-way repeated-measures ANOVA with Bonferroni test for multiple comparisons. Within-group differences were assessed with 1-way repeated-measures ANOVA followed by Dunett test for multiple comparisons. Analyses were performed using GraphPad Prism 5 (GraphPad Software, Inc, La Jolla, CA). A P value of <0.05 was considered significant for all statistical analyses. Figure 1A and 1B reports in vitro receptor interaction of NPA7 with pGC-A (and MasR in pGC-A and MasR overexpressing HEK293 cells, respectively). Background signal was observed in the control when adding NPA7 to parental (nontransfected) HEK293 cells. Importantly, there was significant increase from control in both pGC-A and MasR overexpressing cells with NPA7 thus demonstrating that NPA7 successfully interacts with pGC-A and MasR. Figure 2A reports the action of pGC-A activation with no treatment and increasing concentrations of BNP or NPA7. Compared with no treatment, both BNP and NPA7 followed similar trends with significantly increasing concentrations of cGMP production with both BNP or NPA7 supporting the ability of both BNP and NPA7 to activate pGC-A. Figure 2B reports the action of MasR activation with no treatment and increasing concentrations of Ang 1-7 or NPA7. Compared with no treatment, both Ang 1-7 and NPA7 followed similar trends with significantly increasing concentrations of cAMP production with both Ang 1-7 or NPA7 supporting the ability of both Ang 1-7 and NPA7 to activate MasR.
Results
NPA7 Interaction With pGC-A and MasR in HEK293 Cells
NPA7 Generates the Second Messengers cGMP and cAMP in HEK293 Cells
NPA7 Has Superior cGMP, Hemodynamic, Natriuretic, and Diuretic Actions in Normal Canines as Compared With pGC-A or MasR Activation Alone In Vivo
We measured cGMP production in vivo resulting from MasR activation with Ang 1-7, pGC-A activation with BNP, and dual activation with NPA7 infusion. At a dose of 8.66 pmol×kg , both BNP and NPA7 significantly activated plasma cGMP, urinary cGMP excretion, and renal cGMP generation. Importantly, NPA7 was the most potent generator of cGMP in normal canines, increasing cGMP production to the greatest magnitude compared with an equimolar dose of the endogenous pGC-A activator BNP (Figure 3 ). This was observed for plasma cGMP, urinary cGMP excretion, and renal generation of cGMP.
At baseline, hemodynamic and renal functions were comparable among all 3 treatment groups (Table S1) . During drug infusion, Ang 1-7 did not reduce MAP, and during recovery clearances, this MasR-activating peptide had a moderate MAP-lowering effect. Moreover, as compared with BNP and NPA7, the reduction in MAP was modest ( Figure 4A ). However pGC-A activation with BNP reduced MAP significantly, whereas the effect of NPA7 on MAP was prolonged compared with BNP infusion ( Figure 4A ). In normal canines, NPA7 was the only peptide that showed a significant decrease in systemic vascular resistance ( Figure 4B ). In addition, NPA7 possessed stronger and longer lasting cardiac unloading actions than Ang 1-7 or BNP on pulmonary capillary wedge pressure ( Figure 4C ).
Despite the observed reduction in MAP, infusion with NPA7 significantly increased renal blood flow during infusion, washout, and recovery phase ( Figure 4D ). Moreover, NPA7 possessed potent natriuretic and diuretic actions, which were significantly stronger than observed in single Ang 1-7 or BNP infusion ( Figure 4E and 4F) . Glomerular filtration rate was unchanged from baseline in all groups.
MasR Antagonism With the MasR-i A779 Attenuates NPA7-Mediated BP Lowering, Cardiac Unloading, Systemic Vasorelaxation, Natriuresis, and Diuresis
Addition of A779 to NPA7 infusion significantly reduced plasma cGMP levels, urinary cGMP excretion, and renal cGMP generation (Table) . Figure 5 reports the in vivo hemodynamic responses to MasR-i infusion in normal canines. A779 significantly attenuated responses in MAP and systemic vascular resistance ( Figure 5A and 5B) and also resulted in less cardiac unloading, as represented by significantly less reduction in right atrial pressure ( Figure 5C ) and pulmonary capillary wedge pressure ( Figure 5D ). MasR blockade also attenuated NPA7-induced diuresis and natriuresis ( Figure 5E and 5F).
Discussion
In this study, we report, for the first time, the design, synthesis, in vitro receptor interaction, and the generation of its second messenger and the in vivo cardiorenal actions of a novel, bispecific receptor activating peptide, NPA7. Here, we validated receptor interaction and activation of NPA7 to both pGC-A and MasR and showed in vivo that NPA7 is biologically active with potent and more sustained cardiorenal actions that go beyond MasR or pGC-A alone. Moreover, blockade of MasR attenuated NPA7-mediated cGMP activation, as well as the hemodynamic, natriuretic, and diuretic responses in vivo. The present findings are the first results of a novel and unique MasR activator that possesses Ang 1-7 properties, hence generating in vitro and in vivo actions that represent alternative renin-angiotensin system (RAS) activation. Our findings also report an MasR-activating peptide that also functions as a pGC-A activator.
In this study, we demonstrate receptor interaction in vitro with the alpha luminesce assay of NPA7 in HEK293 cells overexpressing either human pGC-A or human MasR. These receptor interaction studies confirm NPA7's dual receptor system activating properties. Further validation of activation of both receptors in vitro by was investigated by quantifying generation of each receptor's second messenger with NPA7. Specifically, the cGMP and cAMP generating actions of NPA7 followed similar trends to increasing concentrations of the native ligands BNP for pGC-A and Ang 1-7 for MasR reinforcing the bispecific properties of NPA7 to coactivate both receptors. Further studies will be needed to further establish that NPA7 does not also bind to AT1 or AT2 based on the structure of NPA7, which includes the Ang 1-7 sequence in the N terminus.
In normal canines, intravenous infusion with NPA7 resulted in superior diuretic and natriuretic effects, as well as systemic and renal vasodilation and cardiac unloading together with greater cGMP production than either pGC-A or MasR activation alone. Importantly, this favorable cardiorenal profile is NPA7 specific and transcended the effects of single pGC-A activation with BNP or MasR stimulation with Ang 1-7 treatment alone, underscoring the importance of unique design and ability of NPA7 to activate 2 protective receptor systems. Indeed, after addition of the MasR-i A779, NPA7 lost its unique cardiorenal profile with significant blunting of its vasodilatory, cardiac unloading, and diuretic and natriuretic actions. The remaining effects were less effective than observed during BNP infusion, suggesting a synergistic manner of NPA7 receptor activation, again emphasizing the significance of the unique mode of action of this innovative designer peptide. Indeed, the demonstration of the potent in vivo cardiorenal actions of NPA7 linked to MasR, based on MasR blockade, suggests that NPA7 may serve as a carrier or chaperone for Ang 1-7 possibly preventing rapid degradation as occurs with Ang 1-7 alone, thus resulting in robust MasR activation and actions. An additional potential mechanism warranting further studies is the possibility of dimerization of pGC-A and MasR with synergistic actions during coactivation. Indeed, this concept is supported by studies by Leonhardt et al, 33 which provided evidence for heterodimerization and functional interaction of the AT2 receptor and MasR. Although the enhanced cardiorenal actions of NPA7 compared with BNP and Ang 1-7 alone are novel and important, one must emphasize that more chronic studies are needed to establish that such actions are sustained over time.
The unique and striking generation in vivo of cGMP in plasma, urine, and the kidney warrants comments. cGMP has emerged as an important target for cardiovascular therapeutics based on its pleotropic properties in multiple organs and cells. Its generation results from stimulation of membrane-bound pGC-A that we believe is activated by NPA7. Nevertheless, the mechanism(s) of the more sustained increases in cGMP with NPA7 warrants further investigations to examine its full potential as novel therapeutic.
For decades, treatment of CVD, such as hypertension, HF, and most recently metabolic disease, has relied on the beneficial effects of targeting a single-receptor system associated with the underlying pathology. However, the remarkable results with sacubitril/valsartan-a small molecule that inhibits NEP (neprilysin) and AT1R-have provided rationale for the design and development of innovative therapeutics that work on 2 different receptor systems. 5, 34 Further, recent elegant studies have reported that NEP is the principal pathway generating Ang 1-7 in the murine and human kidney and thus inhibition of NEP could reduce the generation of Ang 1-7 and limit its renoprotection. 35 Nonetheless, the promising results of sacubitril/valsartan that antagonizes the AT1R and NEP support the concept of bispecific therapeutics that targets multiple receptor systems has significant efficacy, especially related to the natriuretic peptide system and RAS. In the current study, we have successfully engineered a first-in-class bispecific peptide that directly targets the both of these pathways.
Human genetic epidemiology studies underscore potential important beneficial effects for both ANP and BNP, which activate pGC-A since individuals with genetic variants associated with higher circulating levels of ANP and BNP have lower BP, reduced risk of hypertension, protection from metabolic syndrome, and increased survival. [36] [37] [38] Further, we recently reported the use of adeno-associated virus 9 vector as a gene delivery strategy that allowed long-term (9 months) BNP overexpression in spontaneously hypertensive rats. 25 Specifically, chronic increases in circulating BNP reduced BP and improved myocardial structure and function. Chen et al 27 also reported that chronic subcutaneously administered BNP in human HF improved symptoms and myocardial structure The MasR activator Ang 1-7 is a RAS modulating peptide with an extremely short half-life time, which has limited clinical utility because of its rapid in vivo degradation. 16 This heptapeptide counter-regulates the deleterious effects of Ang II (angiotensin II) and induces vasodilatation and enhances sodium excretion, while promoting antiapoptotic, anti-inflammatory, antithrombotic, and antifibrotic actions. 10, 39, 40 Recently, favorable metabolic actions of Ang 1-7/MasR have been reported, which include protection from obesity-induced hypertension in rodents and induction of brown adipocyte differentiation with upregulation of thermogenesis and improved metabolic profile in diet-induced obesity. 15 The production of Ang 1-7 is highly dependent on degradation of Ang II by ACE2, although Ang 1-7 can also be formed in an Ang I/Ang 1-9 (angiotensin 1-9)-dependent manner that, in part, is also dependent on NEP. [41] [42] [43] [44] Importantly, Ang 1-7 specifically binds to the G-protein-coupled MasR through which it exerts GPCR (G-protein-coupled receptor)-specific actions, such as PKA (protein kinase A)/cAMP pathway activation 45 and NO production. 46 In addition, Ang 1-7 may exert cardioprotective effects via inhibition of cardiodeleterious Ang II/AT1R-dependent G-protein signaling and concomitant selective activation of the cardiorenoprotective β-arrestin pathway. 47, 48 Current cardiovascular therapeutic treatment largely focuses on inhibition of the RAS and targeting Ang II or AT1R. However, inhibition of the hypertensive axis of this system has only limited efficacy, and it has, therefore, been suggested that activation of the alternative, protective arm of the RAS with Ang 1-7 may render an attractive next-generation therapeutic intervention. [49] [50] [51] We now present the first results of a novel therapeutic MasR activator that possesses Ang 1-7 properties, hence generating in vitro and in vivo actions that represent activation of the so-called alternative RAS with synergistic properties when molecularly integrated with a pGC-A activator.
The current study has implications for the treatment of CVD, especially for those disease states in which RAS activation plays a pivotal role (ie, hypertension and HF). Patients with hypertension, and also patients with HF, have disturbed neurohumoral balance, which is characterized by NP deficiency and RAS activation. [52] [53] [54] Treatment with drugs that target both the pGC-A receptor system and MasR may thus have the potential to restore neurohumoral balance in hypertension and HF. Importantly, several recent studies have shown that chronic pGC-A receptor activation, even in preclinical HF, is associated with improved cardiorenal function, left ventricular function or structure, and overall clinical outcomes. 27, 55, 56 Other studies showed that long-term treatment with Ang 1-7 significantly improved cardiac function in diabetic mice and prevented cardiomyocyte hypertrophy, apoptosis, and fibrosis in diabetic mice and rats overexpressing the mouse Ren2 gene. 13, 14, 57, 58 Hence, NPA7 may not only improve hemodynamic function, diuresis, and natriuresis in the short term but may have wide potential application in cardiovascular, renal, and metabolic diseases when chronically used. Thus, future studies are needed to address the full therapeutic potential of this first-in-class peptide and the concept of optimizing therapy with bivalency.
This study has both strengths and limitations. The strengths include (1) the use of human AA sequences of both human BNP (pGC-A ligand) and human Ang 1-7 (MasR ligand) to design and synthesize NPA7 as a bispecific peptide; (2) in vitro binding and second messenger studies supporting bispecific receptor activating properties; and (3) in vivo studies demonstrating cardiorenal actions of NPA7 that extend beyond BNP or Ang 1-7 alone and attenuation of these actions with a MasR blocker. There are important limitations as well, which should lay the foundation for future studies. Such studies should include validating the lack of binding and absence of activation of AT1 and AT2 receptor by NPA7 recognizing AA homologies with Ang II. Moreover, additional in-depth receptor pharmacological experiments are warranted, which can provide intriguing insights on the cross-talk between the pGC-A receptor and the angiotensin receptor family.
In conclusion, we report the design, synthesis, in vitro pharmacology, and in vivo cardiorenal actions of the innovative, first-in-class, bispecific peptide NPA7. This chimera represents a pGC-A receptor activator together with an MasR activator that directly potentiates 2 different receptor systems. NPA7 has potent and sustained cGMP-generating properties, including superior vasorelaxation, cardiac unloading, and natriuretic and diuretic actions. Our findings are significant and demonstrate the successful fusion of 2 different receptor activators into 1 peptide structure that now possesses favorable and clinically relevant cardiorenal actions. Altogether, NPA7 may address the high and unmet need of a novel, bispecific cardiorenoprotective therapeutic for treatment of CVD, such as hypertension and HF. 
